Tectonic Therapeutic, Inc.
TECX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.02 | 0.02 | 0.09 |
| FCF Yield | -15.11% | -67.94% | -313.88% | -60.91% |
| EV / EBITDA | -4.52 | -0.87 | 0.55 | 0.20 |
| Quality | ||||
| ROIC | -40.27% | -121.69% | -347.21% | -402.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 0.95 | 3,020.76 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -44.62% | 57.98% | 3.00% | -0.51% |
| Safety | ||||
| Net Debt / EBITDA | 2.45 | 0.59 | 0.86 | 1.60 |
| Interest Coverage | -542.20 | -293.74 | -732.18 | -530.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -216.56 | -241.95 | -50.29 | -471.71 |